This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Cephalon, Inc.
Cephalon, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States and operates extensively across North America and Europe. Founded in 1987, the company has achieved significant milestones, including its acquisition by Teva Pharmaceutical Industries in 2011, which bolstered its market presence. Specialising in innovative treatments for neurological disorders, pain management, and cancer, Cephalon is renowned for its unique product offerings, such as Provigil and Nuvigil, which address sleep disorders and enhance wakefulness. With a strong commitment to research and development, Cephalon has established itself as a leader in the pharmaceutical sector, consistently delivering high-quality solutions that improve patient outcomes. Its strategic focus on niche therapeutic areas has solidified its position in the competitive biopharmaceutical landscape.
DitchCarbon Score
How does Cephalon, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cephalon, Inc.'s score of 80 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Cephalon, Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years, as indicated by the absence of reported figures. The company is a current subsidiary of Teva Pharmaceutical Industries Limited, which may influence its climate commitments and emissions reporting. As part of its corporate family, Cephalon's climate initiatives and targets are likely aligned with those of Teva Pharmaceutical Industries Limited. However, no specific reduction targets or achievements have been disclosed for Cephalon itself. The absence of documented reduction initiatives suggests that the company may still be in the process of establishing its own climate strategy or reporting framework. Teva Pharmaceutical Industries Limited, as the parent company, may have its own emissions data and climate commitments, which could cascade down to Cephalon. It is essential for Cephalon to develop and communicate its climate commitments to align with industry standards and expectations, particularly in light of increasing scrutiny on corporate sustainability practices.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 438,420,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 613,541,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Cephalon, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
